Generali Asset Management SPA SGR Makes New $4.58 Million Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Generali Asset Management SPA SGR acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,081 shares of the company’s stock, valued at approximately $4,581,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the third quarter valued at $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $31,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $38,000. Finally, Crews Bank & Trust bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $41,000. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $419.52 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The company has a market cap of $34.12 billion, a PE ratio of 39.32, a PEG ratio of 3.41 and a beta of 1.39. The company’s 50-day moving average is $437.74 and its two-hundred day moving average is $445.87.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IDXX shares. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.